Arabic Arabic English English French French German German
dark

Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials

Oramed Pharmaceuticals Inc. announced today that it has enrolled and randomized over 25% of the planned 450 patients for its Phase 3 ORA-D-013-2 trial of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D). Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Prisma Health Partners with TytoCare to Expand Telehealth Offerings

Next Post

ITOCO Welcomes Mr. Erik Gordillo Enamorado as Project Coordinator Carbon Credits and Chief Agricultural Liaison

Related Posts
Total
0
Share